Hector Gutierrez, M.D., professor at the UAB Marnix E. Heersink School of Medicine Department of Pediatrics, Division of Pulmonary and Sleep Medicine, founded Dream a Little Dream, UAB’s first ...

The introduction of highly effective modulator (elexacaftor/tezacaftor/ivacaftor) therapy improved the disease trajectory of cystic fibrosis (CF). However, its ...

As a 40-year-old who lives with cystic fibrosis (CF), Zachary Schulz, PhD, EdS, MPH, is said to be among the reputed “last generation” of patients — those born before the advent of drugs that target ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated disease that differs from person to person. An autosomal recessive disorder ...

Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, ...

When the underlying flaw in cystic fibrosis is finally understood, a simple question leads to a major breakthrough. Then new technology powers a solution that could reshape the future for thousands.

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

Breathing disorders are common in the U.S. with conditions like COPD affecting some 7% of the population and asthma affecting another 10%. Digestive conditions like GERD, acid reflux, Celiac disease ...

Protein clustering mechanism on the cell membrane presents a new therapeutic target for cystic fibrosis. A new study from The Hospital for Sick Children (SickKids) reveals the process underlying ...